TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform

TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform

JACKSONVILLE, Fla., May 23, 2018 /PRNewswire/ — TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, announced today that Peter Hoang, President and CEO, will host a video webinar and slide presentation to discuss the details of the proposed merger with Marker Therapeutics, Inc., on Thursday, May